Copenhagen Economics is an international, expert-driven consulting firm built on a deep knowledge of applied economics. We believe that sound economic analysis, coupled with clear communication of the results, equips decision makers with the Hard Facts and Clear Stories to make superior decisions for the benefit of society.
One of our flagship services is Healthcare & Life Sciences, headed by Partner Julia Wahl. As respected experts in the healthcare and life sciences area, we have vast experience in a range of orphan drug issues. We help companies and governments transform the most complex parts of policy, market-shaping strategies, and conflict cases into actionable steps.
For more information on what we do, please download the material on the right or reach out to us.
We help international pharmaceutical companies assess the impact of potential changes to the Orphan Medicinal Product (OMP) Regulation on their portfolio of orphan drugs. We use risk-adjusted net present value (rNPV) modelling to monetise impacts and conduct exposure analyses to see how, for example, a shorter market exclusivity period will influence the effective protection period of each orphan drug in their portfolio.
This enables our clients to improve their understanding of the impact on revenue, align internally on a common view and position, and steer their public advocacy efforts towards the proposals with the most favourable impacts for themselves and their patients.
We are a knowledge partner with the European Expert Group on Orphan Drug Incentives (OD Expert Group), providing insights that facilitate this multi-stakeholder group’s work, and helping them design a new policy framework for orphan drugs in Europe.
Our work with the OD Expert Group has resulted in the identification of four main needs and fourteen policy proposals that would address these needs. Our experts have supported the group in dialogues with DG Sante and co-presented the fourteen policy proposals in the European Parliament.
Our work with an international pharmaceutical company demonstrated the value to society of innovative, preventive treatment of severe migraine through the use of CGRP inhibitors using of real-world evidence (RWE). While CGRP inhibitors are approved in the EU for people experiencing four or more monthly migraine days, reimbursement in Denmark is only recommended for patients with at least 15 monthly headache days, of which at least 8 are characterised by migraine.
By using a tailored economic model to monetise the value and patient-reported real-world data (RWD), we were able to show that the societal gain from CGRP inhibitors is large, but that the majority of gains are socioeconomic (e.g., labour market implications), which are not directly included in health technology
assessments. This implies that important socioeconomic gains may not be given enough importance in decision-making surrounding migraine management.
At Copenhagen Economics, we take great pride in providing our clients with the Hard Facts and Clear Stories needed to make better decisions for the benefit of their business and, ultimately, society. Engaging Copenhagen Economics ensures fact-based and precise economic arguments when you are preparing for important strategic decisions, whether that be working to reform regulatory impediments, engaging in legal conflicts, or aiming to communicate your economic value to stakeholders.
We assist law firms, private companies, regulators, and policymakers all over the world, and every year, our experts produce over 100 publications based on established research methods, cutting-edge data-processing techniques, and in-depth sector knowledge.
Make a note in your calendar and meet us next year at the EU Pharmaceutical Law Forum 2025, where we will focus on showing you how to turn antitrust into trust.
To find out more before the event, please reach out to Copenhagen Economics Partner Julia Wahl or Service Leader Nikolaj Siersbæk.
